Heart Failure Society of America Hosts Annual Scientific Meeting with Late-Breaking Clinical Research

The Heart Failure Society of America (HFSA) is set to host its 2026 Annual Scientific Meeting (ASM) from October 9-12 in Phoenix, Arizona. This year’s event will feature late-breaking clinical research that could significantly reshape heart failure treatment, covering areas such as pharmacotherapy, imaging and diagnostics, and device therapy.

Dr. Jennifer Thibodeau, the 2026 HFSA Annual Scientific Meeting Program Committee Chair, highlighted the pace of innovation in heart failure care.

The meeting will include two plenary sessions on October 11 and 12, where late-breaking clinical research will be presented. On Sunday, October 11, the first plenary session will cover topics such as the safety and effectiveness of a novel oral therapy, imaging approaches for detecting cardiac amyloidosis, and real-world outcomes from established device therapies. Specifically, the session will feature the following trials:

- Cycle-1 REF: A Phase 2, randomized, double-blind, placebo-controlled, dose-finding study assessing the safety and effectiveness of tovinontrine in patients with chronic heart failure with reduced ejection fraction. - Cycle-2 PEF: A Phase 2, randomized, double-blind, placebo-controlled, clinical study assessing the safety and effectiveness of tovinontrine in patients with chronic heart failure with preserved ejection fraction. - CARDIO-TTRansform: A trial evaluating the effect of eplontersen on health status in patients with transthyretin amyloid cardiomyopathy. - 124I-Evuzamitide Amyloid-targeted PET/CT Scan: A prospective multicenter Phase 3 study cohort exploring the potential for early detection of cardiac amyloidosis. - Cardiac Contractility Modulation Therapy: Real-world clinical outcomes following cardiac contractility modulation therapy. - REBALANCE: A registry presenting real-world outcomes following baroreflex activation therapy.

On Monday, October 12, the second plenary session will delve into novel therapies and real-world outcomes, including:

- ACACIA-HCM: Global efficacy of aficamten in non-obstructive hypertrophic cardiomyopathy. - POSEIDON: Prevalence of cardiovascular inflammation and associated patient characteristics and biomarker profiles in heart failure. - C-MIC III & C-MIC II: Effects of cardiac microcurrent therapy on exercise capacity. - Six-Month Outcomes of Subcutaneous Cardiac Microcurrent Therapy: A comparative analysis of the C-MIC III pilot study with the C-MIC II randomized trial.

In addition to the plenary sessions, the meeting will feature rapid fire oral sessions on Sunday and Monday. These sessions will spotlight key data from late-breaking clinical research. The rapid fire sessions are scheduled as follows:

- Sunday, October 11 | Rapid Fire 1: 10:45 AM - 11:45 AM - Ratio of serum transthyretin to NT-proBNP as a novel prognostic measure for transthyretin amyloid cardiomyopathy. - Colchicine in patients with heart failure and preserved ejection fraction: a crossover trial. - The ReDS-SAFE HF II: remote dielectric sensing-guided decongestion strategy in patients hospitalized for heart failure. - Early eGFR decline following acoramidis initiation and its association with reduced risk of recurrent cardiovascular hospitalizations and mortality. - Gator SCALES-WHF: subcutaneous administration of lasix to eliminate symptoms of worsening heart failure. - Real-world comparative effectiveness study of acoramidis versus tafamidis in transthyretin amyloid cardiomyopathy using the Epic COSMOS data platform. - Dosing and safety of aficamten for symptomatic non-obstructive hypertrophic cardiomyopathy in the ACACIA-HCM trial.

- Sunday, October 11 | Rapid Fire 2: 2:30 PM - 3:30 PM - Ambulatory upright pulmonary artery pressure and risk of HF hospitalization and death. - Hyperbaric oxygen therapy and EECP as adjuvant therapy in heart failure. - Baroreflex activation therapy in heart failure with mildly reduced ejection fraction: first real-world evidence of reduced hospitalization burden. - Cost-effectiveness of ReDS-guided heart failure management. - Pulmonary artery pressure response to loop and thiazide diuretic intensification in heart failure. - Ambient home monitoring of peripheral oedema significantly reduces heart failure events. - Therapeutic sequencing is projected to improve quality-adjusted survival in heart transplant candidates with advanced heart failure.

- Sunday, October 11 | Rapid Fire 3: 5:00 PM - 6:00 PM - Impact of eplontersen on cardiac biomarkers in participants with transthyretin amyloid cardiomyopathy. - Weight loss surgery impact on comprehensive metabolic responses to exercise in heart failure with preserved ejection fraction. - Trajectories of dyspnea after heart failure hospitalization. - Achieving near target-dose quadruple guideline-directed medical therapy before hospital discharge after acute heart failure. - Association of quadruple therapy achievement and biochemically verified medication adherence with outcomes in HFrEF. - The impact of an adaptive patient-centered web application on medication optimization in patients with HFrEF.

- Monday, October 12 | Rapid Fire 4: 12:15 PM, 1:15 PM - TAILORD